Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Tal, I happened to stop by Ihub to see if anything new. After reading your post I tried to find the agreement between amrn and Mochida see below for the only exhibit I could locate.
https://www.sec.gov/Archives/edgar/data/897448/000119312518189948/d602525dex991.htm
Also, an excerpt from 10K 2018. It appears that somewhere a collaborative agreement does exist. I'll continue to research
Tal, not good but they have Pfizer on their side. Their expertise is priceless, we need a BP partner. So what if they have to give up some of their margins. Grow the top line stay focused it will take a couple of years but I'm confident it will happen. It meaning a BO.
meowzo, yup deployed to his ex-wife! LOL
For those who follow HLS please see below,
Meow...very funny
Since I invested in amrn it's prolly not good from drinking too much wine!
.
Invest83, yup, I thought I knew what I invested in with amarin being a believer of the peter lynch theory of investing. Was not aware how crooked the judicial system was. Painful experience.
Invest83, I'll ditto that. As a matter of fact I lmao reading some of meowzo's posts. Whoever this person is has a unique personality.
Talk, house guest again but will read S1 thoroughly later. They will get price hire before offering. S1 is just first filing. SEC will have comment s.
maybe the proceeds will be used to develop the FDC offering???
USE OF PROCEEDS
is this an update of their shelf registration from a few years ago or is it a totally new one?
Form S-3 AMARIN CORP PLC\UK
10K WIZARD 8:35 AM ET 8/2/2023
http://archive.fast-edgar.com/20230802/AS2ZJ22EZ22RA2Z2222P2CYRN4NMZZ22D852
Filed on: August 2, 2023
martinko, no
Bobwayne, Honestly in all the years in the market and many companies I've invested in or shorted have never pulled a 7/18 stunt. What's funny about my experience with the short side is that fraudulent companies usually scam the financials then report overestimated EPS and the stock rallies due to a short squeeze.
At least we know that AMRN isn't in that camp. Unpromise and overdeliver could be the amarin mantra going forward.
seve, you are correct. No Q&A solves many problems also the new CEO will have time to acclimate to the nuances of our quirky company.
Seve, I'm totally discussed with this company. Unfortunately, Sarissa didn't come to the rescue sooner. As usual, the shareholders are left holding the bag.
TTE, what do you mean about 8/2 is after 8/1? Are you joking or is there another implication? LOL
Mongolian, thanks so we wait for 8/2 to find out how bad the real situation is..UGH
Tal, Capt stated that Amarin will not host a conf call or do an earnings release. I'm totally perplexed there isn't anything posted on the website referencing a timeline. The website is not interactive, zero way of contacting the company.
There are just too many assumptions a person has to make in order to have a comfort level with many loose ends. It's a wait and see game.
capt, what's weird is in their 7/18 PR I didn't notice a reference to that question. I'm wondering if there were a couple of different releases. They will have to file a 10Q guess that's when will find out the definitive financials.
anyone tried to contact the company re their Q2 eps and conf call? Their website is useless.
Some AI thoughts, my question; is Lotus Pharma a competitor of Eddingham Pharma
Yes, Lotus Pharma and EddinghamPharma are both pharmaceutical companies that produce and promote a range of pharmaceutical products. Lotus Pharma is an international pharmaceutical company with a global presence, focused on commercializing novel and generic pharmaceuticals, offering patients better, safe, and more accessible medicines1. EddinghamPharma, headquartered in Kowloon, Hong Kong, is a Chinese specialty pharmaceutical company that produces anti-infective drugs, respiratory system disease drugs, and anti-cancer drugs2. Both companies have a diversified product portfolio and are committed to fulfilling large unmet medical needs34. So it is likely that they are competitors in the pharmaceutical industry. Is there anything else you would like to know? 😊
Tat, well at least their time won't be lost dabbling around with a no win scenario.
CBB, This idea may sound a little far fetched but I'm wondering if the FDC approval process would be enhanced by utilizing AI in proving the efficacy of the combo pill? Thinking out loud.
Partnerships are the way to go, I'm sure we'll be hearing more about additional partnerships in the future. The increase in sales and cutting expenses will bring this company in line with BP's thinking about a possible acquisition. Stay tuned
Actually, Holt's experience is mainly in the Asian mkts I think this is a positive for amarin since the China approval is real now that amarin received the $5mill payment from Edding which I never thought would come to fruition.
Amarin's Preliminary Q2 Product Revenue Drops Sequentially; Holt Named CEO; Jobs Cut to Reduce Costs; Shares Slump
MT NEWSWIRES 5:11 PM ET 7/18/2023
Symbol Last Price Change
AMRN 1.43up +0.12 (+9.1603%)
QUOTES AS OF 04:00:00 PM ET 07/18/2023
05:11 PM EDT, 07/18/2023 (MT Newswires) -- Amarin(AMRN) said Tuesday preliminary Q2 product revenue is expected to be about $65 million, compared with $85 million in Q1.
The company had a positive cash flow of $9 million,
Amarin Corporation Shares To Resume Trade At 4:45 p.m. ET
BENZINGA 4:29 PM ET 7/18/2023
Amarin is halted?
maximizing U.S. Cash Flow Through Streamlined Model: Amarin will maintain VASCEPA as a cost-effective option to generics while implementing a reduction in force of all U.S. sales force positions and approximately 30% of non-sales roles. Amarin will retain its managed care and trade organization to support these efforts. The Company will continue to explore innovative approaches to driving revenue as well as the timing of an
Tatsumaki, Please post the portion of the proxy where it talks about a shelf registration for 150mill shs. I'm not finding it. Thx
Amarin Appoints Patrick Holt as President and Chief Executive Officer
HUGIN 4:16 PM ET 7/18/2023
Symbol Last Price Change
AMRN 1.43up +0.12 (+9.1603%)
QUOTES AS OF 04:00:00 PM ET 07/18/2023
DUBLIN, Ireland and BRIDGEWATER, N.J., July 18, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc(AMRN) today announced that the Company’s Board of Directors has appointed Patrick Holt as President and Chief Executive Officer and as a member of the Board of Directors, effective immediately. Aaron Berg, who served as Interim President and CEO since April 2023, will remain with the Company in a senior leadership role.
Mr. Holt brings more than 25 years of leadership in the life sciences industry and significant international operating experience. He most recently served as president of Cordis, Cardinal Health’s global interventional cardiovascular business where he led a turnaround of the business, followed by a transaction process which led to its successful sale. Mr. Holt previously held a variety of senior executive positions across biopharmaceuticals and vaccines at Allergan and Merck.
“We are excited to welcome Pat as our new CEO,” said Odysseas Kostas, M.D., the Chairman of the Board. “Pat’s international and cardiovascular business experience and track record of turnaround success are exactly what the Company needs at this critical time. The Board looks forward to working with Pat to continue to put Amarin(AMRN) on the best path to maximizing shareholder value.”
Mr. Holt said, “The science at Amarin(AMRN) is compelling and aligned to a significant unmet need, and VASCEPA®/VAZKEPA® maintains meaningful untapped value given its clinical profile and proven cardiovascular risk reduction and outcomes. Decisive action is needed to realize Amarin’s full potential, and alongside the entire Amarin(AMRN) team, I am committed to realizing the opportunities inherent in the business to maximize value for patients, physicians, payors and shareholders. I look forward to working with the Board and leadership team as we evaluate and execute on all opportunities to enhance value.”
Dr. Kostas concluded, “On behalf of the Board, I want to thank Aaron for stepping up to lead when he did, working tirelessly over the last few months toward strengthening the Company’s global operations. We look forward to him continuing to contribute in an important way at Amarin.”
About Patrick Holt
Patrick Holt most recently served as president of Cordis, Cardinal Health’s global interventional cardiovascular business and as member of Cardinal Health Inc’s global operating committee. In this role, Mr. Holt led a successful turnaround that included a return to revenue growth, a refocused R&D strategy, as well as sustained enhancements in operational effectiveness delivering margin expansion. Subsequently, he led the transaction process which culminated in the sale of Cordis to Hellman & Friedman in 2021 for an enterprise value in excess of $1 billion. He also previously served as president of Cardinal Health in Asia-Pacific. Prior to his time at Cardinal Health, he served in a variety of senior executive positions across biopharmaceuticals and vaccines at Allergan and Merck. Mr. Holt is an independent non-executive director and audit committee member of Hugel, Inc., a publicly listed biopharmaceutical company and global leader in medical aesthetics. He earned a bachelor’s degree in biochemistry and chemistry from
TTE, this is the definition of TERMINATION taken from the clinical website
A terminated trial indicates that the trial already started recruiting participants but stopped prematurely and recruited participants are no longer being examined/treated 11.
https://clinicaltrials.gov/study/NCT04505098?tab=results
seve333, yes pls see my recent post. EU bio's are up they mention AMRN! Yippee
Pharma Stocks Lead European Equities Traded in the US as American Depositary Receipts Higher Tuesday
MT NEWSWIRES 11:14 AM ET 7/18/2023
Symbol Last Price Change
BPTS 2.8942up +0.6842 (+30.9593%)
GRFS 10.11down +0.29 (+2.9532%)
MOR 8.33up +0.21 (+2.5862%)
TEF 4.0157up -0.0543 (-1.3342%)
DBVT 1.65up +0.01 (+0.6098%)
TRIB 0.88down +0.05 (+6.0241%)
AMRN 1.38down +0.07 (+5.3435%)
ADAP 0.9283down +0.0274 (+3.0414%)
NCNA 0.849up +0.064 (+8.1529%)
BCYC 25.155up -0.605 (-2.3486%)
VOD 9.415down -0.075 (-0.7903%)
QUOTES AS OF 11:15:28 AM ET 07/18/2023
11:14 AM EDT, 07/18/2023 (MT Newswires) -- Pharma stocks led European equities traded in the US as American depositary receipts higher in Tuesday trading as they rose 0.83% to 1,221.50 on the S&P Europe Select ADR Index.
From continental Europe, the gainers were led by biotech firm Biophytis(BPTS) and biopharmaceutical company argenx (ARGX), which rose 35% and 7.4%, respectively. They were followed by biopharmaceutical companies Grifols(GRFS) and MorphoSys(MOR) , which were up 3.6% and 2.8%, respectively.
The decliners from continental Europe were led by dating app operator Spark Networks (LOV) and biopharmaceutical firm Cellectis (CLLS), which fell 5.4% and 2.1%, respectively. They were followed by telecommunications operator Telefonica(TEF) and biopharmaceutical company DBV Technologies(DBVT) , which dropped 1.4% and 1.2%, respectively.
From the UK and Ireland, the gainers were led by biotech firm Trinity Biotech(TRIB) and biopharmaceutical company Amarin(AMRN) , which climbed 8.4% and 7.6%, respectively. They were followed by biopharmaceutical companies Adaptimmune Therapeutics(ADAP) and NuCana(NCNA) , which rose 4.2% and 3.8%, respectively.
The decliners from the UK and Ireland were led by biopharmaceutical firm Biodexa Pharmaceuticals (BDRX) and pharmaceutical company Avadel Pharmaceuticals (AVDL), which declined 5.1% and 3.2%, respectively. They were followed by biopharmaceutical company Bicycle Therapeutics(BCYC) and telecommunications operator Vodafone Group(VOD) , which were down 3.1% and 1%, respectively.
MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited.
Volume hasn't been this heavy in a long time it bottomed out around $1.21. Wouldn't it be wonderful to hear some good news?
DTG, that would make sense. A few years and no word from Amarin but guess cause it was Kaiser's trial. Next.
https://pubmed.ncbi.nlm.nih.gov/33516752/
Capt, have you included the $5mill in the revs for Q2? I'm hoping they don't show it as a receivable. That's not a good sign. I stand by my initial take on Edding. If they don't get their preliminary S1 approved and get Hong Kong listing they don't have the cash to pay the $5mill owed to AMRN.
TCI1, thx it'll be interesting to see if amrn reports the rev in next 10Q filing.
TC11, on pg 62 Edding will owe amrn $15mill upon initial approval. But this doc is 8 yrs old I have no idea what's transpired between the 2 companies since then. If you care to search the original doc see below.
https://www.sec.gov/Archives/edgar/data/897448/000119312515178199/d911115dex101.htm
Sleven, it's just a one page letter requesting an attorney to withdraw pro hac vice or something to that effect...LOL
LBL, Good to see you're still on board with amrn. I check in occasionally patience is needed for a successful turnaround. In the meantime, I got lucky in a couple of other stocks trying to stay positive while AD does his magic.
Tal, You are correct, KM referred to the FDC optimistically. So here we are going into the second half of '23 with no updates. I believe the news of a combo pill will create some activity and interest in the halls of WS. We may be stuck in limbo for a while with no real news from the home office wherever that may be these days...
I feel there's something happening internally, the question is why would they change the feed source for closing quotes? Currently, I think the Bridgewater location is just a hub now that they leased out the majority of the 67,000 sq ft of space. The focus is all overseas. I fear time is not on our side.
BTW thanks for the recent article you posted which includes AD's success stories, there's still some hope.